Mus lepidoides (Muridae, Rodentia) of central Burma is a distinct species of potentially great evolutionary and biogeographic significance.

Zoolog Sci

Laboratory of Ecology and Genetics, Graduate School of Environmental Earth Science, Hokkaido University, Kita-ku, Sapporo, Japan.

Published: May 2010

Mus lepidoides of central Burma (Myanmar) was described 75 years ago but has since been dismissed as a regional variant of the Indian field mouse, M. booduga. DNA sequences of multiple mitochondrial and nuclear genes from recently collected specimens, combined with a fresh morphological reassessment, reaffirm the distinctiveness of M. lepidoides from M. booduga and from all other species of Mus. Mus lepidoides is so distinct in fact that it warrants placement in its own Species Group within subgenus Mus. Molecular and morphological assessments of phylogenetic affinities converge on the exciting possibility that M. lepidoides represents the previously elusive sibling taxon to the Mus musculus Species Group. If confirmed, this relationship would provide the previously missing connection between the main radiation of subgenus Mus in Southeast and South Asia, and the radiation of the M. musculus Species Group in western Asia and Europe. We speculate that a common ancestor of M. lepidoides and the M. musculus Species Group occupied a continuous but episodic tract of xeric habitat that linked central Burma with northern India at various times during the late Pliocene and Quaternary. Further molecular and cytogenetic studies on the phylogenetic position of M. lepidoides clearly represent a high priority in mouse research.

Download full-text PDF

Source
http://dx.doi.org/10.2108/zsj.27.449DOI Listing

Publication Analysis

Top Keywords

species group
16
mus lepidoides
12
central burma
12
musculus species
12
subgenus mus
8
mus
7
species
6
lepidoides
6
lepidoides muridae
4
muridae rodentia
4

Similar Publications

Background: In recent decades, epidemiological and experimental studies have looked into the role of pesticides, particularly the herbicide paraquat, in the development of Parkinson's disease. Horseradish tree (Moringa oleifera) is an ethnobotanical plant with lots of therapeutic potential, but there is a dearth of information on the bioactive properties of the seed alkaloid extracts.

Method: This study examined the modulatory effects of various concentrations of an alkaloid extract from the seeds of Horseradish Tree (Moringa oleifera) on the survival rate of flies exposed to paraquat, as well as certain biochemical and molecular markers related to Parkinson's disease in the heads of the flies.

View Article and Find Full Text PDF

Background: Abnormal glucose metabolism in AD brains correlates with cognitive deficits. The glucose changes are consistent with brain thiamine (vitamin B1) deficiency. In animals, thiamine deficiency causes multiple AD-like changes including memory loss, neuron loss, brain inflammation, enhanced phosphorylation of tau, exaggerated plaque formation and elevated advanced glycation end products (AGE).

View Article and Find Full Text PDF

Background: We identified small molecule tricyclic pyrone compound CP2 as a mild mitochondrial complex I (MCI) inhibitor that induces neuroprotection in multiple mouse models of AD. One of the major concerns while targeting mitochondria is the production of reactive oxygen species (ROS). CP2 consists of two diastereoisomers, D1 and D2, with distinct activity and toxicity profiles.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with neuroinflammation and heightened production of reactive oxygen species (ROS) in the brain from overactive NADPH Oxidase 2 (NOX2). The current study examines whether administration of a novel, brain-penetrant NOX2 inhibitor (CPP11G & CPP11H) reduces amyloid plaque load and improves AD-associated vascular dysfunction in a male APP-PS1 mouse model of AD.

Method: Intraperitoneal injections of CPP11G (n = 1) or CPP11H (n = 2) three times per week began at 9-10 months of age in the treatment APP-PS1 group (15 mg/kg).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Anti-amyloid immunotherapies modestly slow disease progression in early symptomatic AD; addition of other therapeutic modalities may be necessary to achieve larger treatment effects. Therapies that directly target tau can potentially produce substantial clinical benefit because the accumulation of insoluble tau protein is strongly correlated with the progression of AD. Which tau therapies are likely to be efficacious, whether or not to combine them with anti-amyloid therapies, and which individuals are most likely to benefit are important unresolved questions that would require multiple parallel design trials to answer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!